InflaRx (IFRX) Stock Forecast & Price Target

Compare

830 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IFRX Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

InflaRx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IFRX Stock 12 Month Forecast

Average Price Target

$11.14

▲(950.94% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for InflaRx in the last 3 months. The average price target is $11.14 with a high forecast of $24.00 and a low forecast of $2.00. The average price target represents a 950.94% change from the last price of $1.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","25":"$25","-1":"-$1","5.5":"$5.5","18.5":"$18.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5.5,12,18.5,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,2.9169230769230765,4.673846153846154,6.430769230769231,8.187692307692307,9.944615384615384,11.701538461538462,13.458461538461538,15.215384615384615,16.97230769230769,18.729230769230767,20.486153846153844,22.243076923076924,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.9276923076923076,2.695384615384615,3.4630769230769234,4.230769230769231,4.998461538461538,5.766153846153847,6.533846153846154,7.3015384615384615,8.069230769230769,8.836923076923076,9.604615384615384,10.372307692307693,{"y":11.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.2246153846153844,1.2892307692307692,1.3538461538461537,1.4184615384615384,1.483076923076923,1.5476923076923077,1.6123076923076922,1.6769230769230767,1.7415384615384615,1.8061538461538462,1.8707692307692307,1.9353846153846153,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.59,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$24.00

Average Price Target$11.14

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Schwartz

Leerink Partners

Hold

88.68%

Upside

Downgraded

12/03/25

InflaRx downgraded to Market Perform from Outperform at LeerinkInflaRx downgraded to Market Perform from Outperform at Leerink

Sam Slutsky

LifeSci Capital

―

Hold

―

Reiterated

11/12/25

Cautious Hold Rating for InflaRx's INF904 Amid Uncertainties in Trial ResultsInﬂaRx this week announced topline results (LINK) from its Phase 2a open-label, dose-ranging "basket study" tesng INF904 (oral C5aR inhibitor) in chronic spontaneous urcaria (CSU) and hidradenis suppurava (HS).

Steven Seedhouse

Cantor Fitzgerald

$3→$8

Buy

654.72%

Upside

Reiterated

11/11/25

InflaRx price target raised to $8 from $3 at Cantor FitzgeraldInflaRx price target raised to $8 from $3 at Cantor Fitzgerald

Andreas Argyrides

Oppenheimer

$3→$7

Buy

560.38%

Upside

Reiterated

11/11/25

InflaRx price target raised to $7 from $3 at OppenheimerInflaRx price target raised to $7 from $3 at Oppenheimer

Ryan Deschner

Raymond James

$2→$9

Buy

749.06%

Upside

Reiterated

11/11/25

InflaRx price target raised to $9 from $2 at Raymond JamesInflaRx price target raised to $9 from $2 at Raymond James

Yatin Suneja

Guggenheim

$10→$22

Buy

1975.47%

Upside

Reiterated

11/10/25

InflaRx price target raised to $22 from $10 at GuggenheimInflaRx price target raised to $22 from $10 at Guggenheim

Dev Prasad

Lucid Capital

$3→$24

Buy

2164.15%

Upside

Reiterated

11/10/25

InflaRx price target raised to $24 from $3 at Lucid CapitalInflaRx price target raised to $24 from $3 at Lucid Capital

Matthew Keller

H.C. Wainwright

Buy

466.04%

Upside

Reiterated

11/10/25

Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive OptimismValuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from INF904 for CSU (73% contribution; 20% PoS) and HS (27% contribution; 20% PoS) in the U.S. only. We do not value the commercial sales of GOHIBIC yet because it is not a growth stage asset with projected revenue generation that has remained largely nominal.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Schwartz

Leerink Partners

Hold

88.68%

Upside

Downgraded

12/03/25

InflaRx downgraded to Market Perform from Outperform at LeerinkInflaRx downgraded to Market Perform from Outperform at Leerink

Sam Slutsky

LifeSci Capital

―

Hold

―

Reiterated

11/12/25

Steven Seedhouse

Cantor Fitzgerald

$3→$8

Buy

654.72%

Upside

Reiterated

11/11/25

InflaRx price target raised to $8 from $3 at Cantor FitzgeraldInflaRx price target raised to $8 from $3 at Cantor Fitzgerald

Andreas Argyrides

Oppenheimer

$3→$7

Buy

560.38%

Upside

Reiterated

11/11/25

InflaRx price target raised to $7 from $3 at OppenheimerInflaRx price target raised to $7 from $3 at Oppenheimer

Ryan Deschner

Raymond James

$2→$9

Buy

749.06%

Upside

Reiterated

11/11/25

InflaRx price target raised to $9 from $2 at Raymond JamesInflaRx price target raised to $9 from $2 at Raymond James

Yatin Suneja

Guggenheim

$10→$22

Buy

1975.47%

Upside

Reiterated

11/10/25

InflaRx price target raised to $22 from $10 at GuggenheimInflaRx price target raised to $22 from $10 at Guggenheim

Dev Prasad

Lucid Capital

$3→$24

Buy

2164.15%

Upside

Reiterated

11/10/25

InflaRx price target raised to $24 from $3 at Lucid CapitalInflaRx price target raised to $24 from $3 at Lucid Capital

Matthew Keller

H.C. Wainwright

Buy

466.04%

Upside

Reiterated

11/10/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering InflaRx

1 Month

xxx

Success Rate

4/7 ratings generated profit

Average Return

+6.67%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +6.67% per trade.

3 Months

xxx

Success Rate

3/7 ratings generated profit

Average Return

-4.97%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -4.97% per trade.

1 Year

Steven SeedhouseCantor Fitzgerald

Success Rate

4/20 ratings generated profit

Average Return

-20.25%

reiterated a buy rating last month

Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -20.25% per trade.

2 Years

xxx

Success Rate

1/7 ratings generated profit

Average Return

-34.37%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -34.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IFRX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IFRX has received 7 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. IFRX average Analyst price target in the past 3 months is 11.14.

Each month's total comprises the sum of three months' worth of ratings.

IFRX Financial Forecast

IFRX Earnings Forecast

Next quarter’s earnings estimate for IFRX is -$0.18 with a range of -$0.23 to -$0.12. The previous quarter’s EPS was -$0.21. IFRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IFRX has Performed in-line its overall industry.

IFRX Sales Forecast

Next quarter’s sales forecast for IFRX is $135.75K with a range of $0.00 to $764.19K. The previous quarter’s sales results were $27.85K. IFRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IFRX has Performed in-line its overall industry.

IFRX Stock Forecast FAQ

What is IFRX’s average 12-month price target, according to analysts?

Based on analyst ratings, InflaRx NV’s 12-month average price target is 11.14.

What is IFRX’s upside potential, based on the analysts’ average price target?

InflaRx NV has 950.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IFRX a Buy, Sell or Hold?

InflaRx NV has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is InflaRx NV’s price target?

The average price target for InflaRx NV is 11.14. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $24.00 ,the lowest forecast is $2.00. The average price target represents 950.94% Increase from the current price of $1.06.

What do analysts say about InflaRx NV?

InflaRx NV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of IFRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

InflaRx (IFRX) Stock Forecast & Price Target

IFRX Analyst Ratings

IFRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering InflaRx

IFRX Analyst Recommendation Trends

IFRX Financial Forecast

IFRX Earnings Forecast

IFRX Sales Forecast

IFRX Stock Forecast FAQ

Detailed List of Analyst Forecasts